Literature DB >> 21354188

Modulation of the serotonin system by endocannabinoid signaling.

Samir Haj-Dahmane1, Roh-Yu Shen.   

Abstract

The cannabinoid CB(1) receptors and their endogenous agonists, endocannabinoids (eCBs), are ubiquitously distributed throughout the central nervous system (CNS), where they play a key role in the regulation of neuronal excitability. As such, CB signaling has been implicated in the regulation of a myriad of physiological functions ranging from feeding homoeostasis to emotional and motivational processes. Ample evidence from behavioral studies also suggests that eCBs are important regulators of stress responses and a deficit in eCB signaling contributes to stress-related disorders such as anxiety and depression. The eCB-induced modulation of stress-related behaviors appears to be mediated, at least in part, through the regulation of the serotoninergic system. In this article, we review the role of eCB signaling in the regulation of the serotoninergic system with special emphasis on the cellular mechanisms by which cannabinoid CB(1) receptors modulate the excitability of dorsal raphe serotonin neurons.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354188      PMCID: PMC3110547          DOI: 10.1016/j.neuropharm.2011.02.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  100 in total

1.  Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB.

Authors:  M Egertová; M R Elphick
Journal:  J Comp Neurol       Date:  2000-06-26       Impact factor: 3.215

2.  The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

3.  Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice.

Authors:  Sara Jane Ward; Timothy W Lefever; Cavario Jackson; Ronald J Tallarida; Ellen A Walker
Journal:  J Pharmacol Exp Ther       Date:  2008-02-06       Impact factor: 4.030

Review 4.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

5.  Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

Authors:  N Auclair; S Otani; P Soubrie; F Crepel
Journal:  J Neurophysiol       Date:  2000-06       Impact factor: 2.714

6.  Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.

Authors:  J Béïque; C de Montigny; P Blier; G Debonnel
Journal:  Neuropharmacology       Date:  2000-07-24       Impact factor: 5.250

Review 7.  International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Authors:  Liliane Michalik; Johan Auwerx; Joel P Berger; V Krishna Chatterjee; Christopher K Glass; Frank J Gonzalez; Paul A Grimaldi; Takashi Kadowaki; Mitchell A Lazar; Stephen O'Rahilly; Colin N A Palmer; Jorge Plutzky; Janardan K Reddy; Bruce M Spiegelman; Bart Staels; Walter Wahli
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

8.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum.

Authors:  G L Gerdeman; J Ronesi; D M Lovinger
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

9.  Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum.

Authors:  B Szabo; L Dörner; C Pfreundtner; W Nörenberg; K Starke
Journal:  Neuroscience       Date:  1998-07       Impact factor: 3.590

10.  Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.

Authors:  N A Darmani; J J Janoyan; N Kumar; J L Crim
Journal:  Pharmacol Biochem Behav       Date:  2003-07       Impact factor: 3.533

View more
  35 in total

1.  The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Authors:  Mano Aliczki; Istvan Barna; Ibolya Till; Maria Baranyi; Beata Sperlagh; Steven R Goldberg; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2016-01-26       Impact factor: 4.530

Review 2.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

Authors:  Joost Wiskerke; Nicky Stoop; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

4.  Role of CNR1 polymorphisms in moderating the effects of psychosocial adversity on impulsivity in adolescents.

Authors:  Arlette F Buchmann; Erika Hohm; Stephanie H Witt; Dorothea Blomeyer; Christine Jennen-Steinmetz; Martin H Schmidt; Günter Esser; Tobias Banaschewski; Daniel Brandeis; Manfred Laucht
Journal:  J Neural Transm (Vienna)       Date:  2014-07-01       Impact factor: 3.575

Review 5.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

6.  Endocannabinoids blunt the augmentation of synaptic transmission by serotonin 2A receptors in the nucleus tractus solitarii (nTS).

Authors:  James R Austgen; David D Kline
Journal:  Brain Res       Date:  2013-09-13       Impact factor: 3.252

Review 7.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

8.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

9.  Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects.

Authors:  Simon J Evans; Masoud Kamali; Alan R Prossin; Gloria J Harrington; Vicki L Ellingrod; Melvin G McInnis; Charles F Burant
Journal:  J Psychiatr Res       Date:  2012-08-11       Impact factor: 4.791

10.  Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.

Authors:  Ana Belen Lopez-Rodriguez; Alvaro Llorente-Berzal; Luis M Garcia-Segura; Maria-Paz Viveros
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.